BioRestorative Therapies, Inc. (BRTX) |
|
3.4399 0.08 (2.38%)
|
06-26 19:51 |
|
Open: |
3.47 |
Pre. Close: |
3.36 |
|
High:
|
3.47 |
Low:
|
3.32 |
|
Volume:
|
3,891 |
Market Cap:
|
13(M) |
|
|
|
|
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.47 - 3.49 |
3.49 - 3.5 |
|
Low:
|
3.29 - 3.3 |
3.3 - 3.31 |
|
Close:
|
3.42 - 3.44 |
3.44 - 3.46 |
|
Technical analysis |
as of: 2022-06-24 4:38:32 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 4.97 One year: 5.83 |
| Support: |
Support1: 3.06 Support2: 2.55 |
| Resistance: |
Resistance1: 4.26 Resistance2: 4.99 |
| Pivot: |
3.85  |
| Moving Average: |
MA(5): 3.46 MA(20): 3.98
MA(100): 4.39 MA(250): 8.67 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 14.3 %D(3): 13.2 |
| RSI: |
RSI(14): 39.4 |
| 52-week: |
High: 32 Low: 3.06 |
| Average Vol(K): |
3-Month: 25 (K) 10-Days: 16 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BRTX ] has closed above bottom band by 26.3%. Bollinger Bands are 3.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 22 Jun 2022
Highest paid executives on Long Island work at tiny biotech firm BioRestorative Therapies - Newsday
Wed, 22 Jun 2022
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company's ... - The Bakersfield Californian
Mon, 13 Jun 2022
BioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) - GlobeNewswire
Fri, 27 May 2022
BioRestorative Therapies : BRTX Presentation May 2022 - Marketscreener.com
Fri, 29 Apr 2022
BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease - GlobeNewswire
Tue, 12 Apr 2022
Tuesday 4/12 Insider Buying Report: BRTX, WMC - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
3 (M) |
|
% Held by Insiders
|
2.92e+006 (%) |
|
% Held by Institutions
|
19.5 (%) |
|
Shares Short
|
77 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.622e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-57 |
|
Return on Assets (ttm)
|
191 |
|
Return on Equity (ttm)
|
-122.7 |
|
Qtrly Rev. Growth
|
46000 |
|
Gross Profit (p.s.)
|
-0.87 |
|
Sales Per Share
|
-5.36 |
|
EBITDA (p.s.)
|
563.44 |
|
Qtrly Earnings Growth
|
-40.9 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-3 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.65 |
|
Price to Cash Flow
|
-50.24 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
78550 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
